Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05920863 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 11, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: May 2025 to Dec 31, 2025
    • Study completion date: Mar 2026 to Dec 31, 2025
    • Site contact updated
    v4
  2. Start date changed from estimate of Aug 2023 to Jul 1, 2023v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 2023 to Aug 2023
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a monocenter, single-arm, open-label study to evaluate the efficacy and safety of Lenvatinib combined with Tislelizumab and TACE applied as neoadjuvant regimen for the patients of CNLC stage IB and IIA hepatocellular carcinoma with high risk of recurrence Primary outcome: Major pathological response (MPR) Secondary outcomes: pathological complete response (pCR), R0 resection rate, objective response rate (ORR), disease control rate (DCR), treatment-related adverse events (TRAE)
Trial Details
NCT Number NCT05920863
Lead Sponsor Zhejiang Cancer Hospital
Conditions
(from sponsor)		 Hepatocellular Carcinoma, Lenvatinib, Tislelizumab, TACE, Pharmorubicin, Oxaliplatin
Related terms Carcinoma, Hepatocellular
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov